Hovione's $35M CDC Flex line links spray drying to tablets, designed to eliminate scale-up under FDA Q13 guidance.
|Articles|October 29, 2010
Powerful team for excellent separation and Design Space modeling DryLab & Shimadzu UHPLC
Method registration and validation requires detailed results concerning stability and robustness according to a design space.
Advertisement
Method registration and validation requires detailed results concerning stability and robustness according to a design space. The well-known and accepted DryLab* software offers unique tools for supporting method development. Based on defined experiments, the design space of the method is modeled in a 3D cube. Each side represents a combination of parameters (mobile phase composition, temperature and pH) – moving inside this cube, the associated separation is modeled and displayed. Areas with good separation are displayed to visualize the design space of this method.
The accuracy of these calculations has been proven by many users. Prediction of retention, using DryLab’s algorithms, matches very well with real results. The design space model adds real value by providing a framework for small method adaptation, which makes it easier to adapt parameters based on new columns, detection or instrumentation as long these changes are executed within the given ‘space’.
Shimadzu’s UHPLC system is controlled via a software interface to LC solution software, methods can be set in PeakMatch and data files are read directly.
(*DryLab is a product of the Molnár Institute of applied chromatography Berlin)
For further details please visit
Advertisement
Related to this article
This week on PharmTech, Merck diversified its pipeline, USP emphasizes supply chain security, AI systems are examined, and speakers preview their presentations at CPHI Milan and AAPS PharmSci 360.
Capsugel's Bram Baert and Sandrine Picco argue that chasing zero nitrite in pharmaceutical excipients is often impractical and costly. They recommend setting scientifically justified, risk-based limits and consistently staying below them.
Ron Scarboro, Azurity Pharmaceuticals, claims drug reformulation that removes patient barriers must preserve efficacy, urging early cross-functional team alignment.
PharmTech AI Pulse Check episode 2 covers AI data governance, API-gated journals, watermarking limits, and why attribution beats detection in GxP.
The FDA opened an expedited IND pilot, tightened scrutiny of foreign trial data, and finalized a rule recognizing non-animal testing methods. In Europe, the EMA advanced pharmaceutical legislation reform, restricted 2 legacy products, and opened an injectable-iron safety review.
Novartis licenses Abogen's mRNA-encoded T-cell engager for autoimmune disease, raising scale-up questions for mRNA-lipid nanoparticle manufacturing.
Pharma manufacturing spent 90 years learning that producing correct outputs isn't the same as catching your own errors. AI has only learned the first.
Advertisement
Advertisement